Background: Gene therapy targeting the immunosuppressive tumor environment

An interim analysis of the first-in-human trial of Temferon, a gene-modified autologous stem cell therapy, found no dose-limiting toxicities up to the highest dose tested. The study included 24 patients with newly diagnosed glioblastoma and an unmethylated MGMT promoter. Reported in Nature Medicine, this early-stage trial primarily assessed safety and tolerability; whether the treatment improves survival remains to be established.

Glioblastoma is characterized by an immunosuppressive tumor microenvironment dominated by myeloid cells. It is an “immunologically cold” brain tumor in which an antitumor immune response does not develop adequately. Temferon was designed to target this environment by genetically modifying and transplanting patients’ own stem cells. Myeloid cells derived from the transplanted cells are intended to accumulate in the tumor microenvironment, deliver interferon alpha-2 (IFN-α2), and activate local antitumor immunity. This design objective should be distinguished from changes in immune function actually demonstrated in patients.

Key findings: No dose-limiting toxicities up to the highest tested dose

This report is an interim analysis of a first-in-human phase 1/2a dose-escalation trial. Patients were treated in eight cohorts following surgery and radiotherapy. Temferon doses ranged from 0.5×10⁶ to 4.0×10⁶ CD34-positive cells per kg of body weight. Conditioning before transplantation used BCNU or busulfan, with or without thiotepa. The primary endpoint was safety and tolerability within 90 days of cell infusion.

No dose-limiting toxicities were observed up to the highest dose tested. However, adverse events consistent with autologous stem cell transplantation—including abnormal laboratory results, cytopenias, and infections—were reported. The absence of dose-limiting toxicities does not mean that adverse effects or toxicity were entirely absent. The investigators selected busulfan for conditioning in further development.

The genetically modified cells were detected in bone marrow and blood over an extended period, and trace levels of interferon alpha were measured in blood. These findings are distinct from directly confirming long-term engraftment of stem cells within tumors or measuring intratumoral drug concentrations. The provided abstract does not specify the follow-up period for cell detection or interferon concentrations in tumor tissue.

Implications and outlook: Interpreting early safety data and survival outcomes

Median overall survival calculated from diagnosis was 16.7 months, and median progression-free survival was 8.1 months. Most patients were reported to maintain good performance status and quality of life. However, the provided abstract does not give comparator-group information or the statistical uncertainty around the survival estimates, so these figures alone cannot establish that survival was longer than with standard treatment.

This interim analysis provides early safety and tolerability data supporting further clinical development of Temferon in patients with glioblastoma whose MGMT promoter is unmethylated. Further work must more clearly assess long-term safety, the appropriate dose and conditioning regimen, and clinical benefit. The extent of immune activation within tumors and any survival benefit also require additional evidence. The available abstract alone does not establish a treatment standard, an effect of combination with immune checkpoint inhibitors, or an absence of genotoxicity.

The study design and results are available in the Europe PMC bibliographic record and abstract for the Nature Medicine paper.